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Abstract 
Background: The local treatment of Ewing sarcoma of bone involves surgery, radiotherapy or both. The selection of 
treatment depends on the anatomical extent of the tumour, the effectiveness of the proposed treatment, its morbid-
ity, and the expectation of cure. However, not only are there variations in the approach to local treatment between 
individual patients, but also between treatment centres and countries. Our aim was to explore variation in practice 
and develop consensus statements about local treatment.
Methods: A three stage modified Delphi technique was used with international collaborators. This involved an 
expert panel to identify areas of controversy, an online survey of international collaborators and a consensus meet-
ing in London, UK in June 2017. In the consensus meeting, teams of clinicians discussed the local management of 
selected cases and their responses were collected with electronic voting.
Results: Areas of greater or less consensus were identified. The lack of evidence underpinning different approaches 
was noted and areas for collaborative research became apparent.
Conclusion: This has demonstrated that there is an international consensus around many aspects of the local treat-
ment of Ewing sarcoma of bone, including the use of specialist MultiDisciplinary Team (MDT) meetings with access to 
all appropriate treatments. However, considerable variation remains including the use of different staging investiga-
tions, decision making, definitions of response, and radiotherapy doses and timing. Further collaborative work should 
be undertaken to determine the impact of these variations in order to define best practice.
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Background
Ewing sarcoma is the second most common primary 
bone tumour occurring in children and young adults, 
with an incidence of approximately 1 per million. It typi-
cally occurs in the second and third decades of life, with 
80% of patients under 20  years of age at diagnosis [1]. 
Ewing sarcoma can occur in any bone, with a distribution 
reflecting the mass of bone in the skeleton [2].
Ewing sarcoma of bone classically presents with pain 
and an extra-osseous mass arising from the affected 
bone. Characteristic imaging features include a peri-
osteal reaction with or without bone destruction on plain 
radiographs, and an extra-osseous mass on magnetic res-
onance imaging (MRI). Most cases demonstrate a trans-
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Treatment is multidisciplinary and highly specialised, 
involving chemotherapy, radiotherapy and surgery. Local 
therapy decisions are often nuanced, balancing the risks 
and morbidity of surgery and radiotherapy with poten-
tial benefits. Approaches to local treatment vary between 
countries, reflecting different health care structures and 
philosophies. In the EICESS 92 study, differences in local 
treatment approaches were identified: patients from the 
United Kingdom were less likely to receive combined 
modalities (surgery and radiotherapy) than those treated 
in Germany, and there were differences in local relapse 
and overall survival [4].
Recognising these differences, an international consen-
sus meeting to discuss the local treatment of Ewing sar-
coma was held in Birmingham in 2007. This resulted in 
several changes in UK practice, including a pilot in which 
a national Ewing Multidisciplinary Team panel (NEMDT) 
provided central review of cases. This process has been 
associated with changes in treatment approaches, in 
particular the greater use of combined modalities and 
especially of preoperative radiotherapy. In June 2017, a 
second consensus meeting was held in London to explore 
current differences in local treatment approaches and to 
inform the NEMDT panel. The specific objectives were 
to establish standards for current practice, develop con-
sensus statements to guide local treatment decisions and 
identify areas for further research.
Methods
A modified Delphi method was used comprising a three 
stage process of expert panel review, a pre-meeting 
online survey and case review with electronic voting at 
the meeting. Ewing sarcoma of bone arising in all ana-
tomic sites other than the head and neck were included.1 
Soft tissue Ewing sarcomas were excluded.
An expert scientific advisory board was convened in 
early 2017 to develop the content for the conference. This 
panel included clinicians from centres in the UK, Nether-
lands, Germany and the USA (CG, JB, JW, UD, LR, MvdS, 
DP, BS, LJ). Clinical situations in which the approach to 
treatment might vary were identified through discussion 
with the scientific advisory board and from case discus-
sions at the UK NEMDT. A list of potential conference 
participants was compiled aiming to give a wide geo-
graphical representation, including centres recognised 
as having differing approaches to the treatment of Ewing 
sarcoma and participants in the previous consensus 
meeting.
Confirmed conference attendees were asked to com-
plete a pre-meeting survey on the Slido platform (https ://
www.sli.do/) (Additional file 1, Appendix 1). The survey 
asked respondents about their specialty, facilities and ser-
vices at their centre, and general approach to treatment.
The final phase was based around a multidisciplinary 
conference. The programme included introductory pres-
entations summarising the principals of imaging and 
treatment at different anatomical sites. Clinical cases 
were then presented to the audience by two radiologists 
(P O’D and JT, Additional file  1, Appendix  2). Partici-
pants were asked about how they would treat each case, 
and differences in approach were openly discussed. At 
the end of the meeting, cases brought by attendees were 
presented to test the consensus. Participant responses 
were collected electronically using Slido (https ://www.sli.
do/).
Levels of evidence and consensus
Using data from the pre-meeting survey and audience 
responses, consensus was evaluated as strong (more than 
75% of participants/respondents agreeing with a state-
ment), moderate (50–75% of participants/respondents 
agreeing with a statement) or none (no clear agreement). 
Response data are presented for each individual respond-




The pre-meeting survey was sent to 81 clinicians who 
expressed an interest in attending, of whom 58 (72%) 
responded after two reminders. There were representa-
tives from 27 centres in 15 countries, treating a median 
of 6–10 patients a year (range < 5 to > 50 cases per year).
Respondents were orthopaedic surgeons (16/58, 28%), 
paediatric oncologists (15/58, 26%), radiation oncologists 
(11/58, 19%), radiologists (6/58, 10%), medical oncolo-
gists (5/58, 9%), histopathologists (1/58, 2%), and other 
(4/58, 7%). The majority (48/58, 83%) had not attended 
the previous consensus meeting in Birmingham in 2007.
Consensus meeting attendees
There were 59 clinical voting attendees at the meeting. 
Thirty-four centres from 19 countries were represented. 
There were non-voting attendees from charities and 
research bodies. Voting attendees were orthopaedic sur-
geons (18/58, 32%), paediatric oncologists (17/58, 29%), 
radiation oncologists (9/58, 15%), radiologists (3/58, 5%), 
medical oncologists (8/58, 14%), histopathologists (1/58, 
2%), and other (2/58, 4%).
1 Due to constraints on accessing personnel with sufficient expertise, absence 
of adequate data and because of time constraints within the programme.
Page 3 of 13Gerrand et al. Clin Sarcoma Res           (2020) 10:21  
Patient pathways and services
The ideal pathway for patients
Survey respondents confirmed that specialist centres 
routinely perform conventional radiographs in 2 planes 
(Consensus level: strong; Q2.1a, 52/56, 93%) (summa-
rised with other areas of consensus in Table 1), and MRI 
of the whole involved compartment with adjacent joints 
(Consensus level: strong; Q2.1b, 55/56, 98%). The major-
ity perform staging computed tomography (CT) of the 
chest only (Consensus level: moderate; Q2.1d, 34/54, 
63%) with a smaller proportion performing CT of the 
chest, abdomen and pelvis (Consensus level: none; Q2.1e, 
18/45, 40%). Only a minority of respondents (Consensus 
level: none; Q2.1c, 13/55, 24%) were in centres routinely 
offering whole body MRI: more offered positron emis-
sion tomography (PET/CT) (Consensus level: moderate; 
Q2.1f, 37/53, 70%) and/or isotope bone scan (Consen-
sus level: moderate; Q2.1g, 37/56, 66%) and bone mar-
row sampling (Consensus level: moderate; Q2.1h, 40/56, 
71%), depending on the clinical scenario.
The multidisciplinary team
Almost all survey respondents routinely discussed 
patients in a local MDT meeting (Consensus level: strong; 
Q3.1, 51/56, 91%), and a smaller number in a national 
MDT (Consensus level: none; Q3.1, 20/56, 36%) or rou-
tinely with teams in other centres (Consensus level: none; 
Q3.1, 7/56, 13%). In one centre patients were only dis-
cussed selectively outside it, and in an example of good 
practice, another described how the paediatric oncolo-
gist, surgeon and radiation oncologist held a joint consul-
tation with all patients with pelvic and axial tumours at 
the same clinic visit after diagnosis and again at the time 
of a local control decision.
There is variation in guidelines for standard practice, 
as respondents reported adopting the EUROEWING 
2012 trial protocol (Q3.2, 28/51, 55%), ESMO Clinical 
Practice Guidelines (20/51, 39%), British Sarcoma Group 
guidelines (14/51, 27%) and National  Cancer  Institute 
treatment guidelines (4/51, 8%). Other adopted protocols 
included those of the Childrens Oncology Group (COG), 
Scandinavian Sarcoma group, Ewing 2008, the French 
Combinair trial, EW-1 and EW-2 joint studies of Italian 
Paediatric Oncology Group (AEIOP) and the Italian Sar-
coma group, and the hospital’s own guidelines (e.g. those 
of the Tata Memorial Hospital, Mumbai [5]).
Access to diagnostic and treatment services
The majority of respondents had access to whole body 
MRI (Consensus level: strong; Q 3.3, 42/56, 75%), whole 
body PET/CT (Consensus level: strong; 54/56, 96%), spe-
cialist surgical teams with sarcoma expertise (Consensus 
level; strong; 54/56, 96%), expert limb fitting/prosthetic 
services (Consensus level; strong; 52/56, 93%), specialist 
sarcoma rehabilitation (Consensus level; strong; 46/56, 
82%), clinical nurse specialist support (Consensus level; 
strong; 44/56, 79%), clinical trials in Ewing sarcoma 
(Consensus level; strong; 50/56, 89%), and radiotherapy 
delivered by intensity modulated radiotherapy (IMRT) 
(Consensus level; strong; 52/56, 93%). Proton beam ther-
apy was available (Consensus level; strong) in their cen-
tre (7/56, 13%), elsewhere in the country (20/56, 36%), or 
abroad (30/56, 54%). Most had access to specialist end 
of life/palliative care support (Consensus level; strong; 
47/56, 84%).
Most surgeons have access to customised endopros-
theses (4.4, 17/19, 89%), modular endoprostheses (18/19, 
95%), “growing” endoprostheses (18/19, 95%), free flaps/
vascularised grafts (18/19, 95%), rotationplasty (17/19, 
89%), massive allografts (12/19, 63%), and extracorporeal 
irradiation/reimplantation (13/19, 68%).
Timing and approaches to decisions about local treatment
Shared decision making
It was agreed that patients should have the opportunity 
to discuss local treatment options as soon after diagnosis 
as possible (Consensus level: strong; Q4.5o, 15/19, 79% 
agree/strongly agree). Decisions about local treatment 
should be made in collaboration with patients and fami-
lies (Consensus level: strong; Q4.5p, 17/17, 100% agree/
strongly agree).
There was moderate consensus that it is sometimes 
possible to make a decision about radiotherapy based on 
the imaging at presentation (Consensus level: moderate; 
Q5.6c, 14/26, 54% agree/strongly agree) and strong con-
sensus that the radiological response to chemotherapy is 
important when considering local therapy options (Con-
sensus level: strong, Q3.5a, 50/55, 91% strongly agree/
agree).
Decisions about local treatment in the presence of metastatic 
disease
The statement that patients with bone metastases should 
have the same local treatment as those without did not 
reach consensus (Q3.5e, Agree/Strongly agree 30%, 
Undecided 26%, Disagree/strongly disagree 45%). With 
widespread bone metastases, radiotherapy alone to the 
primary tumour is routinely indicated (Consensus level: 
strong; Case 1. 44/54, 81% radiotherapy only to the pri-
mary tumour, also Case 3, 39/56, 70%, Case 17, 26/42, 
62%). In the presence of oligometastatic bone disease, it 
may be reasonable to consider radiotherapy alone for the 
primary tumour (Consensus level: strong; Case5, 35/48, 
73%) as well as radiotherapy to the metastases.
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Table 1 Summary of consensus statements
Patient pathways and services
Imaging at presentation should include
 Conventional X-rays in 2 planes (Strong)
 MRI of the whole involved compartment and adjacent joints (Strong)
 Staging CT of chest (Moderate)
 PET/CT (Moderate)
 Isotope bone scan (Moderate)
 Bone marrow sampling (Moderate)
 Patients should be managed within a properly constituted MDT (Strong)
Services should have access to the following
 Whole body MRI (Strong)
 Whole body CT/PET (Strong)
 Specialist surgical teams (Strong)
 Expert limb fitting/prosthetic services (Strong)
 Specialist sarcoma rehabilitation (Strong)
 Clinical nurse specialist support (Strong)
 Clinical trials (Strong)
 Radiotherapy by IMRT (Strong)
 Radiotherapy by proton beam (Strong)
Timing and approaches to decisions about local treatment
 Patients should have the opportunity to explore local treatment options as soon after diagnosis as possible (Strong)
 Decisions about local therapy should be made in collaboration with patients and families (Strong)
 It is possible to make a decision about radiotherapy based on the imaging at presentation in some situations (Moderate)
 The radiological response to chemotherapy is important when considering local therapy options (Strong)
 With widespread bone metastases, radiotherapy alone to the primary tumour is routinely indicated (Strong)
 With oligometastases, radiotherapy alone may be considered as well as treatment to the oligometastases (Strong)
 Patients with pulmonary metastases should be considered for the same local treatment as those without (Strong), including potentially morbid resec-
tions (Moderate)
Pathology and molecular biology
 Patients should have biopsies in the bone cancer centre (Strong)
 Core needle biopsies or open biopsies are preferred (Strong)
 Specimens should be tested for cytogenetic abnormalities (Strong)
 Oligometastases in lymph nodes or bone should be biopsied (Moderate)
 Tissue is banked for research (Strong)
 Assessment of histological response is important when considering the effectiveness of local treatment (Strong)
 An adequate response to chemotherapy should be taken as > 90% necrosis (Moderate)
 Surgical margin status is a reliable indicator of tumour left in the patient (Moderate)
 An adequate surgical margin is one in which there is no viable tumour at the edge of the resection specimen (Moderate)
Surgery
 The surgical resection should be planned to include the biopsy track (Strong)
 An adequate surgical margin is one in which all of the anatomical structures involved at presentation are completely removed (Strong)
 Where feasible it is reasonable to consider resection of peri-lesional oedema (Moderate)
 The radiological response to neoadjuvant chemotherapy should be considered when planning surgery (Strong)
 Pelvic spacers may have a role in reducing the morbidity of radiotherapy (Moderate)
 Radiotherapy has a negative impact on outcomes after endoprosthetic replacement (moderate)
 Radiotherapy has an negative impact on outcomes after allograft reconstruction (Moderate)
 Radiotherapy does not make surgery more difficult technically (Moderate)
 There is no role for debulking surgery when a tumour cannot be completely resected (Strong)
 Local recurrence has an impact on overall survival (Strong)
Page 5 of 13Gerrand et al. Clin Sarcoma Res           (2020) 10:21  
In contrast, patients with pulmonary metastases should 
be considered for the same local treatment as those with-
out (Consensus level: strong; Q3.5f, 34/52, 65% agree/
strongly agree). It is reasonable therefore to consider 
potentially morbid resections, for example of the pelvis, 
in the presence of pulmonary metastases (Consensus 
level: moderate; Case 2, 31/48, 65%).
Pathology and molecular biology
Biopsy techniques and approaches
Patients usually have biopsies in the bone cancer centre 
(Q2.2, Consensus level: strong), with a core needle biopsy 
by a radiologist (Q2.3, 26/55, 47%), surgeon (14/55, 25%), 
or open incisional biopsy by a surgeon (12/55, 22%). 
Fine needle aspirate was only infrequently used (2/55, 
4%). Biopsy tracks are usually marked so that they can 
be excised at the time of definitive surgery (Q2.4, 38/56, 
68%).
Biopsy specimens are routinely tested for molecular 
abnormalities, including the EWS translocation (Q2.5, 
53/56, 95%). Lymph nodes that may be involved on imag-
ing should be sampled before chemotherapy (Q2.6, Con-
sensus level: moderate, 28/56, 50%). Similarly, suspected 
bone oligometastases should be biopsied (Q2.7, Consen-
sus level: moderate, 29/56, 52%). Tissue should be rou-





 Tumours which cross the midline in the sacrum are not considered resectable because of the morbidity associated with surgery (Strong)
 Tumours with major visceral involvement or requiring pelvic organ removal may also be considered too morbid to resect (Moderate)
 Definitive radiotherapy is indicated for unresectable sacral tumours (Strong)
 Protons may be advantageous in the sacrum (Strong)
 Preoperative radiotherapy may be preferred when the tumour volume is large (Moderate)
 Radiotherapy is likely to be associated with increased complication rates (Strong)
Spine
 Protons may be of some benefit in the spine (Strong)
 The type of spinal reconstruction can affect the choice of radiotherapy treatment modality (Strong)
 Patients with a possible Ewing’s tumour of the spine without neurological signs should have a biopsy before decompressive surgery (Strong)
 Urgent surgery is recommended if there is a Ewing’s tumour of the spine causing neurological compromise (Moderate)
 Radiotherapy is usually indicated after decompressive surgery (Strong) and should include the original tumour volume and all areas potentially con-
taminated by surgery (Strong)
Chest
 A pleural effusion in relation to a chest wall tumour is not a definite indication for radiotherapy preoperatively (Moderate)
 A pleural effusion in relation to a chest wall tumour may be an indication for post operative radiotherapy (Moderate)
 Pleural involvement with a primary tumour may be an indication for preoperative (None) or postoperative (Moderate) radiotherapy
Extremity
 Amputation is considered less often than for osteosarcoma (Strong)
 Amputation may be indicated if negative margins cannot otherwise be achieved (Moderate)
 If resection of a distal leg tumour would lead to inadequate margins or a foot with poor function, below knee amputation is indicated (Strong)
 Amputation is less often recommended in the upper extremity (Moderate)
 In the proximal tibia, amputation does not necessarily lead to better outcomes than proximal tibial replacement and radiotherapy (Moderate)
 Radiotherapy can be added to surgery in the tibia but accepting a high risk of local complications (Moderate), therefore preoperative radiotherapy 
may be preferred (Moderate)
Local therapy in advanced disease
 Suspected solitary bone metastases should be biopsied at presentation if possible (Strong)
 Solitary bone metastases may be treated by surgery, radiotherapy or both if the morbidity is acceptable (Strong)
 If there are widespread bone metastases, radiotherapy is indicated when symptomatic (Strong)
 Potentially involved lymph nodes should have sampling or biopsy before chemotherapy if possible (Strong)
 It is appropriate to surgically resect lymph nodes if there is suspicion of tumour involvement (Moderate)
 It is reasonable to consider radical surgery such as amputation or hemipelvectomy to treat locally recurrent disease if there are no metastases (Strong)
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Assessment of response to chemotherapy
The histological response to chemotherapy is important 
when considering the effectiveness of local treatment 
(Consensus level: strong, Q3.5b, 50/54, 92% strongly 
agree/agree). Some respondents agreed the definition of 
an adequate response to chemotherapy should be taken 
as > 90% necrosis (Consensus level: moderate. Q3.5c, 
20/31, 64% strongly agree/agree), with others prefer-
ring 100% necrosis (Consensus level: weak. Q3.5d, 8/32, 
25% strongly agree/agree). However, it was recognised 
that the increasing use of preoperative radiotherapy 
will change the interpretation of necrosis in resection 
specimens.
Assessment of surgical margins
Surgical margin assessment is a reliable predictor of 
tumour remaining in the patient (Consensus level: mod-
erate; Q3.5g, 34/52, 66% strongly agree/agree). An ade-
quate surgical margin is one in which there is no viable 
tumour at the edge of the resection specimen (Consensus 
level: moderate; Q35h, 33/53, 63% strongly agree/agree). 
The statement that an adequate surgical margin is one 
in which all of the anatomical structures involved before 
chemotherapy have been completely removed did not 
reach consensus in the pre-meeting survey (Q3.5i, 17/47, 
37% Strongly agree/agree, 16/47, 35%, strongly disagree/
disagree). There was strong consensus that local recur-
rence at the primary site has an impact on overall sur-
vival (Consensus level: strong; Q4.5f, 19/20, 95% agree/
strongly agree).
Surgery
Principles of surgery for Ewing sarcoma
When planning surgical resection the biopsy track should 
be removed (Consensus level: strong, Q4.1, 17/19, 89% 
“yes”).
In the pre-meeting survey, many respondents did not 
consider resecting all of the volume/anatomical struc-
tures involved before chemotherapy (Consensus level: 
moderate; Q4.2, 10/19, 53% “no”). However, most sur-
geons considered resecting all of the volume/anatomical 
structures involved after chemotherapy (Consensus level: 
strong; Q4.3, 16/19, 84% “yes”).
Where feasible it is reasonable to consider resection of 
peri-lesional oedema which might contain tumour (Con-
sensus level: moderate; Case 4, 32/47, 68%),
The radiological response to neoadjuvant chemother-
apy should be considered when planning surgery (Con-
sensus level: strong; Q4.5n, 17/20, 85% agree/strongly 
agree).
Pelvic spacers should be considered to reduce the mor-
bidity of radiotherapy (Consensus level: moderate; Q4.5j, 
11/20, 55% agree/strongly agree).
Complications of surgery
Radiotherapy has a negative impact on outcomes, espe-
cially infection and prosthetic failure, after endopros-
thetic replacement of a long bone (Consensus level: 
moderate; Q4.5b, 15/21, 71%), and after allograft recon-
struction (Consensus level: moderate; Q4.5c, 15/21, 71%). 
Respondents thought radiotherapy did not make surgery 
more difficult technically (Consensus level: moderate; 
Q4.5d, 12/21, 57%).
Surgeons did not reach consensus about the statement 
that some patients at high risk of surgical complications 
should complete chemotherapy before surgical treatment 
(Consensus level: none; Q4.5a, 10/21, 48% strongly agree/
agree vs 29% disagree/strongly disagree).
When is a tumour inoperable?
There is no role for debulking surgery when a tumour 
cannot predictably be completely resected (Consensus 
level: strong; Q4.5e, 18/20, 80% disagree/strongly disa-
gree that debulking surgery should be considered).
Radiotherapy
Indications for and timing of radiotherapy
Radiotherapy may be given pre-operatively, post-opera-
tively or as definitive treatment. Tumour volume may be 
considered as a relative indication when making a rec-
ommendation for radiotherapy (Consensus level: none; 
Q5.4d, Q83).
There was no consensus as to whether pathologi-
cal fracture at presentation was a definite indication for 
preoperative radiotherapy (Q75, with radiotherapy rec-
ommended always/very often in 29%, and rarely/never 
in 48%), although there was some agreement that radio-
therapy should be considered postoperatively (Consensus 
level: moderate; Q87, 11/21, 53% Very often/always, com-
pared with 24% rarely/never).
There was agreement that involved lymph nodes should 
be included in radiotherapy treatment volumes (Con-
sensus level: moderate; Q91, 19/26, 73% agree/strongly 
agree).
If complete resection is possible based on initial imag-
ing, the decision about radiotherapy can await assess-
ment of histological response (Consensus level: strong; 
Case 11, 43/56, 77%).
A poor radiological response to neoadjuvant chemo-
therapy is a relative indication for preoperative (Con-
sensus level: moderate; Q77, 61% sometimes/very often/
always. Consensus level: strong; Case 9, 47/50, 94%) or 
postoperative radiotherapy (Consensus level: strong; 
Q89, 20/23, 87%, sometimes/very often/always).
Preoperative radiotherapy may be given when an 
inadequate (marginal) margin is anticipated on imag-
ing. There was strong consensus that a 2  mm margin 
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after resection and preoperative radiotherapy does not 
require further radiotherapy (Consensus level: strong, 
Case 8, 35/46, 76%). Tumours close to critical anatomi-
cal structures which would be morbid to resect surgically 
(e.g. major nerve or blood vessel) should be considered 
for preoperative radiotherapy (Consensus level: moder-
ate; Q68, 12/24, 50% always/very often). The expectation 
of a close or positive surgical margin on the pre-chemo-
therapy scan is not a definite indication for preoperative 
radiotherapy (Consensus level: none; Q69). However, if 
a close or positive surgical margin is expected based on 
the post chemotherapy scan, preoperative radiotherapy 
should be considered (Consensus level: moderate; Q70, 
14/24, 59%).
Indications for postoperative radiotherapy include 
viable tumour at the surgical margin (Consensus level: 
strong; Q79, 25/25, 100%, Very often/always), incom-
plete excision of the pre-chemotherapy tumour volume 
(Consensus level: moderate; Q80, 15/25, 60% very often/
always) and poor histological response (Consensus level: 
moderate; Q81, 17/25, 68% very often/always), usually 
defined as < 90% necrosis, although there was variation 
in the level of histological response deemed acceptable to 
avoid radiotherapy (Consensus level: none; Case 9).
Complete excision and good histological response are 
needed to avoid radiotherapy. It is reasonable to add 
postoperative radiotherapy with a margin of < 2  mm 
and < 90% necrosis (Consensus level: strong; Case 7, 
46/56, 82%).
Radiotherapy dose
For pre-operative radiotherapy, there was no consensus 
for dose (range 45–55.8 Gy), with doses of 45 Gy (27%), 
50 Gy (32%), and a range of ‘other’ doses (41%) reported, 
including 50.4 Gy, 54 Gy and 55.8 Gy.
For post-operative radiotherapy, there was also no con-
sensus, although the doses used were generally higher 
than for pre-operative radiotherapy (range 45–60  Gy). 
Doses reported were 45  Gy (18%), 50  Gy (23%), ‘other’ 
(50%), and ≥ 60  Gy (10%). The ‘other’ group included 
42 Gy, 50.4 Gy, 54 Gy, and 55.8 Gy.
For definitive radiotherapy, there was again a lack of 
consensus, although as with post-operative radiotherapy, 
doses were generally higher than for pre-operative radio-
therapy (range 45–70.2 Gy). Doses reported were 50 Gy 
(11%), 60 Gy (32%), > 60 Gy (11%) and ‘other’ (47%). The 
‘other’ group included 45  Gy, 54  Gy, 55.8  Gy, 59.4  Gy, 
70.2 Gy.
For all radiotherapy indications, fraction sizes of 1.5 Gy, 
1.8 Gy and 2 Gy were reported.
Selection of modalities for planning and delivery 
of radiotherapy
There is an expectation that the indications for proton 
beam treatment will expand as it becomes more available 
(Consensus: moderate; Q92, 16/24, 67% agree/strongly 
agree).
Insertion of a pelvic spacer can be considered to allow 
delivery of the prescribed radiotherapy dose by reducing 
the dose to normal tissue structures, in particular bowel 




There was strong consensus that sacral tumours which 
cross the midline should not be resected because the 
morbidity of resection including loss of bladder, bowel 
and sexual function is thought unacceptable (Consensus 
level: strong; Q4.6, 15/20, 75%. Also Case 15, 36/46, 78%). 
Similarly, major visceral involvement requiring pelvic 
organ removal would mean that most surgeons would not 
recommend resection (Consensus level: moderate; Q4.6, 
14/20, 70%, Case 5). Definitive radiotherapy is indicated 
for sacral tumours for which surgery is considered too 
morbid (Consensus level: strong; Case 15, 44/44, 100%). 
Protons may be advantageous in this situation in terms of 
delivery of optimal dose, and reduction in normal tissue 
toxicity (Consensus level: strong; Case 15, 38/47, 81%).
Tumours in the pelvis may be selected for radiotherapy 
preoperatively (Consensus level: moderate; Q5.4h, 73% 
sometimes/very often/always) or postoperatively (Con-
sensus level: strong; Q5.5h, 20/22, 91% sometimes/very 
often/always).
Preoperative radiotherapy may be preferred when the 
tumour volume is large (Consensus level: moderate; Case 
2, 26/50, 52%; Case 10, 40/49, 82%; Consensus level: 
strong, Case 10, 39/52, 75%).
Reconstruction is likely to be associated with more 
complications if radiotherapy has been given and influ-
ences the choices for reconstruction (Consensus level: 
strong, Case 10, 43/49, 88%).
Spine
Proton beam radiotherapy may be of some benefit in the 
spine (Consensus level: strong; Case 12, 41/44, 93%: Case 
13, 44/50, 88%). Where combined modality treatment 
with surgery and radiotherapy is indicated, it is recog-
nised that the type of reconstruction can affect the choice 
of radiotherapy treatment modality (Consensus level: 
strong; Case 13, 32/43, 74%).
Patients who present with a possible Ewing tumour of 
the spine without neurological signs should have a biopsy 
as a response to systemic treatment is likely and may 
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allow intralesional decompressive surgery to be avoided 
(Consensus level: strong; Case 14; 49/50, 98%).
If there is deteriorating or objective neurological com-
promise, urgent surgery is recommended (Consensus 
level: moderate; 29/48, 60%), rather than biopsy and 
chemotherapy/radiotherapy. Radiotherapy is invariably 
indicated after decompressive surgery (Consensus level: 
strong; Case 14, 41/46, 89%), and should include the 
original tumour volume and all areas potentially con-
taminated by surgery (Consensus level: strong; Case 14, 
45/51, 88%).
There was no consensus about the use of craniospinal 
radiotherapy for patients with epidural disease (Q5.6d).
Chest
A pleural effusion in association with a chest wall tumour 
is not a definite indication for radiotherapy preopera-
tively (Consensus level: moderate; Q5.4e, 12/21, 57% 
rarely/never), but may be postoperatively (Consensus 
level: moderate; Q5.5e, 10/20, 50% always/very often). 
However, pleural involvement with a primary tumour 
may be an indication for radiotherapy either preop-
eratively (Consensus level: none; Q5.4f, 7/21, 34% very 
often/always) or postoperatively (Consensus level: mod-
erate; Q5.5f, 10/20, 50% very often/sometimes. See also 
Case 17).
Extremity
Amputation is considered less often than for other 
extremity bone tumours (Consensus level: strong; Q4.5l, 
16/20, 80%), but may be considered if negative surgical 
margins cannot otherwise be achieved (Consensus level: 
moderate; Q4.7, 14/20, 70%). Alternatively, if resection of 
a tumour would be associated with inadequate margins 
or a foot with poor function, below knee amputation may 
be indicated (consensus level: strong; Case 6. 43/54, 80%).
Respondents indicated that amputation would be less 
often recommended in an upper extremity tumour (Con-
sensus level: moderate; Q4.5l, 10/20, 50%).
In proximal tibial tumours, it was agreed that amputa-
tion does not necessarily lead to better outcomes than 
proximal tibial replacement and radiotherapy (Consensus 
level: moderate; Q4.5k, 10/20, 50%). In the tibia, it is rea-
sonable to add radiotherapy to surgery while accepting a 
high risk of local complications (Consensus: moderate; 
Case 3, 30/51, 59%). In this situation, preoperative radio-
therapy is preferred (Consensus level: moderate; Case 3, 
36/49, 73%). Preferred reconstructive options would be 
autograft, endoprostheses or allograft (Case 3). Amputa-
tion is a reasonable alternative for some patients.
In the proximal femur, if complete resection is deemed 
feasible, then either pre or post op radiotherapy can be 
considered. (Case 11).
In a case with an intraarticular tumour at the elbow, 
radiotherapy was recommended (Consensus level: 
strong; Case 18, 34/47, 72%), preferably postoperatively 
(Consensus level: moderate; Case 18, 31/50, 62%).
Local therapy in advanced disease
General approach to patients with advanced disease
Oligometastases in  bone A suspected solitary bone 
metastasis should be biopsied at presentation if possible 
(Consensus level: strong; Case 4, 45/51, 88%). If there is 
more than one suspected metastasis it may be reason-
able to biopsy more than one (Consensus level: moderate; 
Case 5. 32/56, 57%).
The statement that resection of bone metastases 
improves survival was not supported (Consensus level: 
none; Q4.5h), but bone metastases may be resected if the 
morbidity is acceptable (Consensus level: strong; Q4.5i, 
16/20, 80% agree/strongly agree). A solitary metasta-
sis should be treated by surgery, radiotherapy or both 
(Consensus level: strong; Case 4, 47/52, 90%, resec-
tion, radiotherapy or both). With greater numbers of 
bone metastases, individual treatment of all metastases 
becomes more difficult, but if possible radiotherapy to 
two lesions is reasonable (Consensus level: strong; Case 
5, 49/51, 96%).
Where widespread bone metastases are present, radio-
therapy is indicated when symptomatic (Consensus level: 
strong: Case 1, 50/57, 88%).
Lymph node involvement Staging by PET/CT is more 
likely to detect soft tissue/lymph node involvement. 
Potentially involved lymph nodes should have sampling 
or biopsy before chemotherapy whenever possible (Con-
sensus level: strong; Case 6; 44/50, 88%). It is appropriate 
to surgically resect lymph nodes if there is suspicion of 
tumour involvement (Consensus level: moderate; Q4.5g, 
14/20, 70%. Also Case 6, consensus level: moderate; 31/56, 
56%).
Local therapy in relapsed disease
It is reasonable to consider radical surgery such as ampu-
tation or hemipelvectomy to treat locally recurrent Ewing 
sarcoma if there are no metastases (Consensus level: 
strong; Q4.5m, 18/20, 90% agree/strongly agree. Case 16, 
31/48, 65%).
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Discussion
Our aim was to define existing international consen-
sus about the local treatment of Ewing sarcoma of bone 
in order to inform specialist MDTs and identify areas in 
which collaboration to develop more evidence aimed at 
strengthening future consensus might be worthwhile. We 
have identified an engaged and supportive professional 
and patient community which actively contributed to 
this project and constituted a key strength of this report. 
Although we have attempted to collect objective data 
about treatment, our description of the strength of con-
sensus is necessarily subjective. The conclusions of this 
paper should therefore be treated with caution and are 
for consideration by treating teams rather than definitive 
recommendations.
The ideal patient pathway and staging
The urgent referral of patients with a suspected Ewing 
sarcoma of bone to a specialist centre is established prac-
tice [6]. Initial evaluation with plain radiographs and MRI 
of the whole involved compartment and adjacent joints 
is universally applied. However, we have shown variation 
in systemic staging with some centres performing CT of 
abdomen and pelvis as well as chest. There is greater vari-
ation in imaging of the skeleton with centres most often 
performing whole body isotope bone scan and bone 
marrow sampling. PET/CT was also widely offered and 
may be as useful as bone marrow sampling [7]. However 
whole body MRI scan was not routinely offered and given 
recent evidence about its sensitivity may be a better stag-
ing investigation [8]. Further evaluation of the optimal 
staging investigations for Ewing sarcoma is warranted.
The multidisciplinary team and decision making
The treatment of patients with Ewing sarcoma requires 
a properly constituted MDT with expertise in medi-
cal oncology, radiotherapy, and surgery [6, 9]. We have 
shown there is almost universal use of MDT discussion, 
and adoption of a wide range of existing treatment pro-
tocols. Wide discussion outside the treating MDT, for 
example in a national forum or with another centre is not 
usual in the majority of countries, although the EICESS 
92 experience indicates that a more unified approach 
could be explored to determine if it will improve out-
comes for patients and has been adopted by the CESS 
group in Germany [4, 10]. The wider adoption of national 
or international MDT discussions has some intuitive 
appeal but demands further evidence.
Timing and approaches to decisions about local treatment
Complete resection of the primary tumour continues as 
the preferred approach, with radiotherapy as an alterna-
tive if surgery is not feasible, unacceptably morbid or if 
the prognosis is poor (for example with widespread bone 
metastases). The majority of patients receive combined 
treatment. Evidence in favour of one or other treatment 
approach comes predominantly from retrospective stud-
ies and is difficult to interpret because there is an inher-
ent bias in treatment selection.
Shared decision making
Shared decision-making involves a collaborative 
approach to treatment decisions based on an under-
standing of the patient’s priorities for their own lives: we 
showed strong consensus that decisions should be made 
together with patients and families as early as possible 
in the treatment pathway. However, there is no evidence 
that this approach is of benefit in patients with Ewing 
sarcoma specifically and standard mechanisms for sup-
porting high quality decisions do not exist. There is an 
opportunity to develop these and to use existing outcome 
data to allow patients, families and treating teams to 
make fully informed treatment decisions [11].
Decisions about local treatment in the presence of metastatic 
disease
Patients with bone metastases at diagnosis have a poor 
prognosis [12], and therefore there was an expected 
strong consensus for avoiding morbid surgery. The treat-
ment of multiple bone metastases with radiotherapy is 
likely reasonable if they are small in number and easily 
treatable, but there is little evidence for improved out-
comes associated with this approach. The better progno-
sis of patients with pulmonary metastases alone supports 
a more aggressive approach to local treatment, including, 
for example, surgical resection of the pelvis. However, 
decisions about local treatment may be more nuanced 
given the lower expectation of cure.
Pathology and molecular biology
Biopsy techniques and approaches
The principles of biopsy of musculoskeletal tumours are 
well established. An image guided needle biopsy is the 
most widely adopted technique, with open incisional 
biopsy preferred by some. The latter has the advantage 
of providing more material for diagnostic studies and 
research at the risk of greater local contamination. This 
may become more important as biological studies, for 
example whole genome sequencing become integrated 
into the diagnostic and treatment pathway.
Biopsy of other areas of potential involvement, such as 
lymph nodes or bone metastases can also be important 
at presentation and before chemotherapy, particularly if 
aggressive local treatment such as surgical excision might 
be considered. Evidence is needed to support this more 
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aggressive approach to oligometastatic disease including 
the identification of patients who might benefit.
Assessment of response to chemotherapy
There was strong consensus that the histological response 
to chemotherapy was important when considering the 
effectiveness of local treatment, although interpretation 
of this is made more difficult after preoperative radio-
therapy. The level at which a response is defined as ade-
quate varies: Greater than 90% necrosis was accepted by 
many participants, but others only consider a complete 
histological response as ‘adequate’ [13]. Standardisation 
of radiological response parameters is also needed.
Surgery
Principles of surgery for Ewing sarcoma
At presentation, Ewing sarcomas typically have a large 
extra-osseous mass which infiltrates local anatomi-
cal structures. Although the mass may reduce following 
chemotherapy, viable tumour cells may remain in these 
infiltrated structures. The principle that all of the struc-
tures involved at presentation should either be surgically 
removed or included in the radiation field has become 
established within the NEMDT in recent years and 
reached strong consensus after discussion at this meet-
ing. This included the resection of perilesional oedema 
if reasonable. In practice, however, local treatment deci-
sions are often more pragmatic, driven by an understand-
ing of what is reasonable, the associated morbidity and 
the expectation of cure.
Surgical margin assessment aims to evaluate whether 
there is residual tumour in the local site, and there is 
some variation in what is believed to be an adequate sur-
gical margin. Future assessments may need to go beyond 
the traditional evaluation of the resected specimen and 
be combined with response to chemotherapy to give a 
better risk stratification for local recurrence.
Complications of surgery
A key consideration in local treatment is the interac-
tion between surgery and radiotherapy. Radiotherapy 
is associated with an increased risk of wound complica-
tions and deep implant infection [14]. Furthermore, the 
smaller treatment volume and potential for lower doses 
have increased the use of preoperative radiotherapy, par-
ticularly in the pelvis. Disadvantages include an increase 
in complications of surgery or that surgery may be more 
technically challenging if tissue planes become difficult 
to identify. However, the latter was not supported in the 
meeting.
Complications of surgery such as infection or wound 
failure can delay the resumption of chemotherapy. There-
fore in some cases where the risk of such complications 
is sufficiently high, it has been suggested that surgery is 
delayed until the end of chemotherapy. However, no con-
sensus was reached on this question.
Radiotherapy
Radiotherapy is most frequently delivered with photons, 
although as access improves, more patients are receiv-
ing proton beam treatment. Photon radiotherapy is best 
delivered via a 3D-conformal CT-plan, or increasingly 
with intensity modulated radiotherapy, which frequently 
allows for superior dose delivery and normal tissue spar-
ing. For some patients, proton beam therapy may offer an 
advantage in delivering the prescribed radiotherapy dose 
(if it is at the higher end of the dose range) or in sparing 
normal tissues and reducing late toxicity.
We have shown variations in the approach to radiother-
apy and different approaches to the treatment of patho-
logical fractures, lymph nodes and the indications for and 
timing of radiotherapy. Further evaluation of the optimal 
delivery of radiotherapy is required in clinical trials.
Anatomical site variations
Pelvis/sacrum
About a quarter of Ewing sarcomas involve the pelvis 
and/or sacrum [15]. Pelvic tumours tend to be larger, 
with a higher risk of metastasis and poorer survival 
[15]. The soft tissue mass associated with a pelvic Ewing 
tumour can be large and may involve adjacent critical 
anatomical structures such as the iliac vessels, bladder 
and rectum. Local recurrence rates after resection of pel-
vic tumours can be higher than other sites [16]. Retro-
spective series suggest that patients treated with surgery 
have better overall survival [17] and that those treated 
with surgery and radiotherapy together have lower local 
recurrence rates [18], however there is great variability in 
preferences for local control [19, 20]. Furthermore, more 
recent reports have suggested definitive proton treatment 
can be associated with high local control rates [21].
Surgical resection of a pelvic or sacral sarcoma is rou-
tinely associated with surgical complications, long term 
morbidity and loss of physical function, particularly after 
resection of the acetabulum and major (often sacral) 
nerves [22, 23]. The determination of what is a resect-
able tumour in the pelvis depends to a large extent on the 
degree of morbidity acceptable to the patient and their 
family. There was consensus that tumours which were 
too morbid to resect include those which cross the mid-
line in the sacrum and those which would require major 
visceral resection. These are useful guides for treating 
teams and demand the longer-term collection of physical 
functioning outcomes to inform decision making.
After preoperative radiotherapy, the expected 
increased risk of complications means that surgeons 
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are less likely to recommend allograft or endoprosthetic 
reconstruction. After periacetabular resection, a “hang-
ing hip” reconstruction may therefore be preferred [24].
Spine
Two thirds of patients with Ewing sarcoma of the spine 
undergo urgent decompression at presentation which 
complicates subsequent local management [25]. How-
ever, there was moderate consensus that a patient with 
spinal cord compression and neurological compromise 
from Ewing sarcoma should undergo urgent surgical 
decompression if it is indicated. Radiotherapy should 
then include all of the original tumour volume and 
other areas potentially contaminated.
For those with spinal tumours who do not have neu-
rological compromise, it is appropriate to treat first 
with urgent biopsy and chemotherapy which may lead 
to a reduction in tumour size and avoid urgent surgical 
decompression.
The decision about what is resectable within the spine 
should be made by a surgeon with relevant site-specific 
experience working within a multidisciplinary team. 
There may be some benefit to surgical excision if the 
morbidity is acceptable, but there are no randomised 
trials and local control rates with radiotherapy alone 
are high [16, 26]. When surgery is undertaken consid-
eration should be given to the type and positioning of 
instrumentation used in reconstruction. Traditional 
titanium implants may significantly impair the ability to 
deliver PBT and have a deleterious effect on follow-up 
MRI imaging.
Chest
The use of radiotherapy for chest wall tumours is 
related predominantly to pleural involvement either 
before or after surgery. A pleural effusion is not on its 
own an indication for radiotherapy [27].
Extremity
Ewing sarcoma of the extremity should be treated with 
wide resection if feasible, and in the majority limb spar-
ing surgery is possible, with amputation rates around 
8.4% [15]. Amputation is associated with the best local 
control rates, but usually the greatest loss of function. 
It should be pointed out that while surgery is certainly 
favoured secondary to other important considerations, 
overall prognosis may not be influenced by local con-
trol modality [28]. Exceptions to this rule include sig-
nificant resections of the foot or tibia which would 
result in lower levels of physical functioning than 
transtibial amputation [29]. In the upper limb there 
is a greater emphasis on the preservation of function, 
and teams may rely more on adjuvant radiotherapy to 
achieve local control.
Reconstruction of the proximal tibia is associated with 
relatively high surgical complication rates, including 
infection [30]. Adding radiotherapy to a surgical recon-
struction may increase this risk and may lead to a failed 
reconstruction. In this situation therefore, there was con-
sensus in favour of preoperative radiotherapy but recog-
nition that amputation may be a reasonable alternative 
for some patients.
Local therapy in metastatic and relapsed disease
Although bone metastases are associated with a dis-
mal outcome, there was support for a more aggressive 
approach using focussed radiotherapy and possibly sur-
gery if there are only a small number of bone metastases 
[31]. Similarly, there was some support for an aggressive 
approach to potentially involved lymph nodes, including 
biopsy or sampling at presentation and surgical resection 
and/or radiotherapy as part of definitive local therapy.
After isolated local relapse, there will routinely be 
a question about whether further systemic treatment 
should be supplemented with local treatment. There was 
strong consensus that it was reasonable to consider even 
radical surgery such as hemipelvectomy in this situation, 
but it is important to balance the definite morbidity of 
the treatment with any small potential to improve the 
overall poor outcome, particularly in early relapse. All of 
these settings need further evidence to guide clinicians.
Future research
The variation in practice recorded in this initiative high-
lights areas in which research and clinical trials could 
be usefully performed in order to develop stronger evi-
dence-based approaches to primary tumour manage-
ment. These include:
• The role of new imaging technology for more accu-
rate staging.
• Developing methods for early and shared decision-
making about local treatment.
• The role and benefit of specialist national MDT 
review.
• Definitions of radiological and histological responses 
to chemotherapy.
• Studies of type, timing and dose of radiotherapy. As 
an example, incorporation of prospective questions 
about radiotherapy delivery within the next genera-
tion of European clinical trials for Ewing sarcoma are 
already well advanced.
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Re-examination of these areas of consensus in a further 
international workshop, preceded by an updated survey, 
would certainly be worthwhile.
Conclusion
Achieving consensus about local therapy decisions in 
Ewing sarcoma is possible but several areas lacking con-
sensus remain. There is consensus about the central role 
of an MDT, and the services patients require for optimal 
treatment. However, variation in approaches between 
centres have been described, the significance of which is 
uncertain. Areas where clinical trials may be developed 
have been identified.
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